



2 February 2026

**PYC THERAPEUTICS LIMITED
PRO-RATA NON-RENOUCEABLE ENTITLEMENT OFFER**

NOTICE UNDER SECTION 708AA(2)(f) CORPORATIONS ACT 2001 (CTH)

This notice is given by PYC Therapeutics Limited (**Company**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (**Act**) as notionally modified by Australian Securities and Investment Commission Corporations (Non-Traditional Rights Issues) Instrument 2016/84 (**ASIC Instrument 2016/84**) and ASIC Corporations (Disregarding Technical Relief) Instrument 2016/73 (**ASIC Instrument 2016/73**).

Where applicable, references in this notice to sections of the Act are to those sections as modified by ASIC Instrument 2016/84 and ASIC Instrument 2016/73.

The Company has announced a pro-rata non-renounceable entitlement offer (**Entitlement Offer**) of 3 new fully paid ordinary shares (**New Shares**) for every 5 shares held as at 4.00pm (Perth time) on 4 February 2026 by shareholders with a registered address in Australia, New Zealand and certain other jurisdictions in which the Company decides to extend the Entitlement Offer.

The Company confirms that:

- 1 The New Shares will be offered without disclosure under Part 6D.2 of the Act.
- 2 This notice is being given under section 708AA(2)(f) of the Act.
- 3 As at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Act as they apply to the Company (accounting requirements); and
 - (b) sections 674 and 674A of the Act (continuous disclosure requirements).
- 4 As at the date of this notice, there is no excluded information of the type referred to in sections 708AA(8) and 708AA(9) of the Act that is required to be set out in this notice under section 708AA(7) of the Act.
- 5 The issue of New Shares under the Entitlement Offer is not expected to have a material effect or consequence on the control of the Company.

This ASX announcement was approved and authorised for release by the Board of PYC Therapeutics Limited.